Open AccessProstanoid receptors in GtoPdb v.2021.2
Author(s) -
Lucie H. Clapp,
Mark A. Giembycz,
Ákos Heinemann,
Robert L. Jones,
Shuh Narumiya,
Xavier Norel,
Yukihiko Sugimoto,
David F. Woodward,
Chengcan Yao
Publication year - 2021
Publication title -
iuphar/bps guide to pharmacology cite
Language(s) - English
Resource type - Journals
ISSN - 2633-1020
DOI - 10.2218/gtopdb/f58/2021.2
Subject(s) - prostanoid , prostacyclin , receptor , thromboxane a2 , thromboxane receptor , thromboxane , chemistry , prostaglandin , endogeny , endocrinology , pharmacology , medicine , biology , platelet , biochemistry
Prostanoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Prostanoid Receptors [694]) are activated by the endogenous ligands prostaglandins PGD2, PGE1, PGE2 , PGF2α, PGH2, prostacyclin [PGI2] and thromboxane A2. Differences and similarities between human and rodent prostanoid receptor orthologues, and their specific roles in pathophysiologic conditions are reviewed in [448]. Measurement of the potency of PGI2 and thromboxane A2 is hampered by their instability in physiological salt solution; they are often replaced by cicaprost and U46619, respectively, in receptor characterization studies.